Understanding the Structure of PLD3 in Alzheimer's Disease
Author Information
Author(s): K. Ishii, S. J. Hermans, M. E. Georgopoulou, T. L. Nero, N. C. Hancock, G. A. N. Crespi, M. A. Gorman, J. H. Gooi, M. W. Parker
Primary Institution: St Vincent's Institute of Medical Research and University of Melbourne
Hypothesis
The study aims to determine the crystal structure of PLD3 to understand its role in Alzheimer's disease.
Conclusion
The study found that PLD3 is a functional nuclease but does not exhibit phospholipase activity, providing insights into its role in Alzheimer's disease.
Supporting Evidence
- PLD3 has been validated as a therapeutic target for treating Alzheimer's disease.
- The crystal structure reveals a bilobal structure with a catalytic site located between the lobes.
- Key single nucleotide polymorphisms were mapped onto the structure, providing insights into their impact on Alzheimer's disease.
Takeaway
Scientists looked at a protein called PLD3 to see how it works in the brain and found it helps break down DNA but doesn't do what some other similar proteins do.
Methodology
The crystal structure of PLD3 was determined using X-ray crystallography at 2.3 Å resolution, and various biochemical assays were performed to assess its activity.
Limitations
The study does not address the potential need for cofactors that might be required for phospholipase activity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website